Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Osteoporosis 1Neoplasms 1Neoplasm Metastasis 1Hypogonadism 1Genetic Diseases, Inborn 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Alendronate × Genitourinary × Clear all
NCT00019695 2024-03-04

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

NCT00048841 2010-03-02

Prevention of Osteoporosis in Men With Prostate Cancer

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 3 Completed
112 enrolled
Genitourinary

Hypogonadism, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡